NYSE:LH - Laboratory Corp. of America Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$130.48 -3.32 (-2.48 %)
(As of 12/19/2018 01:19 AM ET)
Previous Close$133.80
Today's Range$129.66 - $134.98
52-Week Range$129.66 - $190.35
Volume1.51 million shs
Average Volume762,595 shs
Market Capitalization$13.86 billion
P/E Ratio13.59
Dividend YieldN/A
Beta0.99
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests, as well as with Baptist Health. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Receive LH News and Ratings via Email

Sign-up to receive the latest news and ratings for LH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNYSE:LH
Previous SymbolNYSE:LH?
CUSIP50540R40
Phone336-229-1127

Debt

Debt-to-Equity Ratio0.83
Current Ratio1.55
Quick Ratio1.44

Price-To-Earnings

Trailing P/E Ratio13.59
Forward P/E Ratio11.87
P/E Growth1.41

Sales & Book Value

Annual Sales$10.44 billion
Price / Sales1.26
Cash Flow$14.2757 per share
Price / Cash Flow9.14
Book Value$67.09 per share
Price / Book1.94

Profitability

EPS (Most Recent Fiscal Year)$9.60
Net Income$1.27 billion
Net Margins13.27%
Return on Equity17.13%
Return on Assets7.23%

Miscellaneous

Employees60,000
Outstanding Shares100,900,000
Market Cap$13.86 billion
OptionableOptionable

Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions

What is Laboratory Corp. of America's stock symbol?

Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

How were Laboratory Corp. of America's earnings last quarter?

Laboratory Corp. of America Holdings (NYSE:LH) released its quarterly earnings data on Wednesday, October, 24th. The medical research company reported $2.74 EPS for the quarter, missing analysts' consensus estimates of $2.88 by $0.14. The medical research company earned $2.83 billion during the quarter, compared to the consensus estimate of $2.84 billion. Laboratory Corp. of America had a net margin of 13.27% and a return on equity of 17.13%. The company's revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.46 EPS. View Laboratory Corp. of America's Earnings History.

When is Laboratory Corp. of America's next earnings date?

Laboratory Corp. of America is scheduled to release their next quarterly earnings announcement on Tuesday, February 5th 2019. View Earnings Estimates for Laboratory Corp. of America.

What guidance has Laboratory Corp. of America issued on next quarter's earnings?

Laboratory Corp. of America issued an update on its FY18 earnings guidance on Wednesday, October, 24th. The company provided earnings per share guidance of $11.25-11.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.53. The company issued revenue guidance of $11.34-11.44 billion, compared to the consensus revenue estimate of $11.43 billion.Laboratory Corp. of America also updated its FY 2018 guidance to $11.25-11.45 EPS.

What price target have analysts set for LH?

17 brokerages have issued 1 year price objectives for Laboratory Corp. of America's shares. Their predictions range from $155.00 to $202.00. On average, they anticipate Laboratory Corp. of America's stock price to reach $178.3333 in the next twelve months. This suggests a possible upside of 36.7% from the stock's current price. View Analyst Price Targets for Laboratory Corp. of America.

What is the consensus analysts' recommendation for Laboratory Corp. of America?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Corp. of America in the last year. There are currently 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Laboratory Corp. of America.

What are Wall Street analysts saying about Laboratory Corp. of America stock?

Here are some recent quotes from research analysts about Laboratory Corp. of America stock:
  • 1. Canaccord Genuity analysts commented, "We lower our estimates and PT from $162 to $155, which now uses a 13.8x multiple on our lower ’19 Adj. EPS of $11.30." (12/2/2018)
  • 2. According to Zacks Investment Research, "LabCorp posted a dismal quarter with adjusted earnings and revenues both missing the respective Zacks Consensus Estimate. While increasing acquisitions and organic volume expansion positively contributed to LabCorp Diagnostics business in the quarter, the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth. The revised 2018 guidance also fails to inspire us about the company’s future performance. Covance Drug Development, however, has reported sturdy growth. This uptrend was primarily owing to strategic acquisitions and robust organic growth. Nevertheless, adverse currency headwind impacted the top line. This apart, the current economic uncertainty including challenging reimbursement scenario for testing labs and utilization weaknesses are looming headwinds for LabCorp. In the past three months, LabCorp has underperformed its industry." (11/30/2018)

Has Laboratory Corp. of America been receiving favorable news coverage?

Media coverage about LH stock has trended somewhat positive on Wednesday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Laboratory Corp. of America earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of Laboratory Corp. of America's key competitors?

Who are Laboratory Corp. of America's key executives?

Laboratory Corp. of America's management team includes the folowing people:
  • Mr. David P. King, Chairman, CEO & Pres (Age 62)
  • Mr. Glenn A. Eisenberg, CFO & Exec. VP (Age 57)
  • Mr. F. Samuel Eberts III, Chief Legal Officer, Chief Compliance Officer, Sr. VP & Sec. (Age 58)
  • Mr. John D. Ratliff, Chief Exec. Officer of Covance Drug Devel. (Age 58)
  • Mr. Gary M. Huff, Chief Exec. Officer of Labcorp Diagnostics (Age 51)

Who are Laboratory Corp. of America's major shareholders?

Laboratory Corp. of America's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.73%), Vanguard Group Inc (10.73%), BlackRock Inc. (9.06%), Nordea Investment Management AB (1.96%), OppenheimerFunds Inc. (1.65%) and JPMorgan Chase & Co. (1.63%). Company insiders that own Laboratory Corp. of America stock include Adam H Schechter, David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, Jean-Luc Belingard, Kerrii B Anderson, Lance Berberian, Lisa J Uthgenannt, M Huff Gary, R Sanders Williams and Robert E Mittelstaedt Jr. View Institutional Ownership Trends for Laboratory Corp. of America.

Which major investors are selling Laboratory Corp. of America stock?

LH stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, HealthCor Management L.P., Bessemer Group Inc., Mitsubishi UFJ Trust & Banking Corp, Janus Henderson Group PLC, Loomis Sayles & Co. L P, Skandinaviska Enskilda Banken AB publ and Jennison Associates LLC. Company insiders that have sold Laboratory Corp. of America company stock in the last year include Adam H Schechter, David P King, Edward T Dodson, Glenn A Eisenberg, Kerrii B Anderson, Lisa J Uthgenannt, M Huff Gary and R Sanders Williams. View Insider Buying and Selling for Laboratory Corp. of America.

Which major investors are buying Laboratory Corp. of America stock?

LH stock was purchased by a variety of institutional investors in the last quarter, including Rehmann Capital Advisory Group, BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., PointState Capital LP, Deutsche Bank AG, Acadian Asset Management LLC and Calamos Advisors LLC. View Insider Buying and Selling for Laboratory Corp. of America.

How do I buy shares of Laboratory Corp. of America?

Shares of LH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Laboratory Corp. of America's stock price today?

One share of LH stock can currently be purchased for approximately $130.48.

How big of a company is Laboratory Corp. of America?

Laboratory Corp. of America has a market capitalization of $13.86 billion and generates $10.44 billion in revenue each year. The medical research company earns $1.27 billion in net income (profit) each year or $9.60 on an earnings per share basis. Laboratory Corp. of America employs 60,000 workers across the globe.

What is Laboratory Corp. of America's official website?

The official website for Laboratory Corp. of America is http://www.labcorp.com.

How can I contact Laboratory Corp. of America?

Laboratory Corp. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company can be reached via phone at 336-229-1127 or via email at [email protected]


MarketBeat Community Rating for Laboratory Corp. of America (NYSE LH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  462 (Vote Underperform)
Total Votes:  896
MarketBeat's community ratings are surveys of what our community members think about Laboratory Corp. of America and other stocks. Vote "Outperform" if you believe LH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel